Braidwell LP Decreases Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Braidwell LP trimmed its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 28.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 707,240 shares of the company’s stock after selling 274,969 shares during the quarter. Braidwell LP owned about 1.75% of Keros Therapeutics worth $41,069,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in KROS. Alkeon Capital Management LLC raised its position in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares during the period. Assenagon Asset Management S.A. raised its position in Keros Therapeutics by 814.6% in the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock valued at $12,990,000 after purchasing an additional 199,245 shares during the period. FMR LLC raised its position in Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after purchasing an additional 179,374 shares during the period. Emerald Advisers LLC purchased a new stake in Keros Therapeutics in the third quarter valued at approximately $9,032,000. Finally, Vanguard Group Inc. raised its position in Keros Therapeutics by 7.9% in the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after purchasing an additional 113,563 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

Shares of KROS opened at $58.55 on Friday. Keros Therapeutics, Inc. has a 1-year low of $27.31 and a 1-year high of $73.00. The stock has a market cap of $2.37 billion, a PE ratio of -11.24 and a beta of 1.23. The firm has a fifty day moving average price of $59.45 and a 200 day moving average price of $52.27.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same period last year, the firm earned ($1.33) earnings per share. The business’s revenue was up 4750.0% on a year-over-year basis. As a group, equities analysts expect that Keros Therapeutics, Inc. will post -5.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Guggenheim assumed coverage on Keros Therapeutics in a research report on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price on the stock. Scotiabank assumed coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $88.89.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.